Amoytop Biotech posts strong nine-month revenue growth despite Q3 profit dip

For the nine months ending September 30, 2025, Amoytop Biotech reported a total operating income of RMB 2,479,547,947.46, marking a 26.85% increase compared to the same period in 2024. Net profit attributable to shareholders reached RMB 666,123,781.87, up 20.21% year-over-year. Basic earnings per share for the period stood at RMB 1.64, a 20.59% rise from the previous year.

The company's total assets grew by 24.12% to RMB 3,786,248,215.19 as of September 30, 2025, compared to year-end 2024. Research and development investment also saw a substantial increase of 38.53% to RMB 311,840,338.05. Cash flow from operating activities surged by 61.33% to RMB 471,118,206.70, primarily due to higher cash receipts from product sales.

Despite these gains, the current period's profit attributable to shareholders decreased by 4.63% to RMB 238,229,670.66, and total profit declined by 9.08% to RMB 254,725,608.89 compared to the third quarter of 2024. Non-recurring losses, including significant increases in other non-operating expenses, also impacted the quarter's profitability.